(Q46240839)

English

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy

scientific article published on 18 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

phosphorylation

0 references

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

Takayuki Kinoshita

12

object named as

Takayuki Kinoshita

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Chikako Shimizu

3

object named as

Chikako Shimizu

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Yasuhiro Fujiwara

13

object named as

Yasuhiro Fujiwara

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

1

object named as

Kan Yonemori

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

9

object named as

Kenji Tamura

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

8

object named as

Masashi Ando

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Noriyuki Katsumata

10

object named as

Noriyuki Katsumata

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

6

object named as

Makiko Ono

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

2

object named as

Koji Tsuta

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Yutaka Hatanaka

4

object named as

Yutaka Hatanaka

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

author name string

Kaoru Hashizume

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Tsutomu Kouno

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Tadashi Hasegawa

11

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

publication date

18 November 2008

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Medical Oncology

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

26

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

344-349

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

https://scigraph.springernature.com/pub.10.1007/s12032-008-9127-2

0 references

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in tumour biological markers during primary systemic chemotherapy (PST).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in endometrial PTEN expression throughout the human menstrual cycle

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19016009

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-008-9127-2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19016009

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46240839&oldid=2101817527"